FDA grants first CLIA waiver for nucleic acid-based flu diagnostic test
The U.S. Food and Drug Administration today granted the first waiver to allow a nucleic acid-based test, the Alere i Influenza A B test, to be used in a greater variety of health care settings. The test was previously only available for use in certain laboratories. Influenza, commonly known as the flu, is a contagious respiratory illness caused by two types of influenza viruses: Type A and Type B. Flu infections can range from mild
Read More